Bellicum to be Added to the NASDAQ Biotechnology Index

HOUSTON--(BUSINESS WIRE)-- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index® (Nasdaq: NBI). This addition will be effective prior to market open on Monday, December 21, 2015.

The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on an annual basis. All securities in the NASDAQ Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit www.nasdaq.com.

About Bellicum Pharmaceuticals

Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151214006297/en/

Investors:
Bellicum Pharmaceuticals
Alan Musso, CFO, 832-384-1116
[email protected]
or
Media:
BMC Communications
Brad Miles, 646-513-3125
[email protected]

Source: Bellicum Pharmaceuticals, Inc.

You May Also Be Interested In

• TechMediaBreaks – Wrap Technologies, Inc. (NASDAQ: WRAP) Q2 Revenue Jumps 103% as Gross Margin Expands to 75%
• LMB Investors Have Opportunity to Join Limbach Holdings, Inc. Fraud Investigation with SBS Law
• Table Trac, Inc. Reports 2026 Second Quarter Earnings